Swapping is Better than Cycling in Psoriatic Arthritis Save
A real-world cohort study suggests that psoriatic arthritis failing to respond to TNF inhibitors (TNFi) may do better if they subsequently swap to an IL-17 inhibitor (IL-17i), rather than cycling to another TNFi.
They categorized outcomes according to if cycling from TNFi to another TNFi (CG), swap from TNFi to IL17i (SG1) or from IL17i to TNFi (SG2). The Kaplan-meier CG, SG1 and SG2 2-years retention rates were:
- CG 51% (TNFi to another TNFi)
- SG1: 58% (Swap from TNFi to IL17i)
- SG2: 34% (Swap from IL17i to TNFi)
Retention rates were most influenced by SG1 strategy (HR 0.53; p = 0.02), age (HR 0.98; p = 0.003), Disease Activity PsA (HR 1.11; p < 0.0001), year of switch (HR 1.78; p < 0.0001).
The findings of this observational study support the PsA swapping from TNFi to IL17i might be more effective than cycling TNFis.
ADD THE FIRST COMMENT
Disclosures
The author has no conflicts of interest to disclose related to this subject
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.